Bold Capital Partners is an early-stage venture capital firm investing in life sciences, healthcare, and frontier tech companies.

Bold Capital Partners

Thynk Capital possess a historical investment performance in the top 1% of venture capital.  Focused on investments in early stage pharma and biotech companies focused on extending HealthSpan and major diseases of Aging including Alzheimer's, Dementia, Kidney Disease, Cancer, Cardiovascular, Diabetes, Frailty, and Rare Disease which affect over 25% of the population and growing at 10%/year.

Thynk Capital

KIZOO provides mentoring, seed and early-stage financing with a focus on rejuvenation biotech.  Having been entrepreneurs, VCs and mentors in both, high growth tech and biotech companies theirselves for many years with multiple exits and massive value created for the founders, they now bring this experience to the emerging field of rejuvenation biotech - a young industry that will eventually become much bigger than today's largest technology markets. ​ As part of the Forever Healthy Group, they directly support the creation of startups that turn research on the root causes of aging into therapies and services for humans. ​ Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference.

KIZOO Technology Capital

Lauder Partners, LLC is an entity investing in various realms of the technology field. Lauder invest both directly in companies as well as in funds - both venture and others. Since it primarily invests the capital of Gary Lauder and family members, we don't provide much information to the public.

Lauder Partners

Western Technology Investment is a venture capital firm that specializes in offering acquisition financing to revenue-generating firms. The firm provides debt and lease financing to venture capital backed technology companies.

Western Technology Investment

The Longevity Fund is investing in human longevity.

The Longevity Fund

For Good Ventures is an investment firm that supports innovative, disruptive technologies changing the world for good. The firm invests in for-profit, positive-impact businesses, and funds in private markets positioned for scalable, positive change. It specifically invests in companies that fundamentally benefit humanity or the environment as a core focus of their business model.

For Good Ventures

SAVEarth Fund

Formic Ventures is a diversified venture capital firm that makes early-stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful.

Formic Ventures

Prime Movers Lab is a venture capital firm that seeks to invest in startups reinventing energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture.

Prime Movers Lab

Leslie Ventures

Kuelbs Family Office provides the capital needed but would let continues to run business way.

Kuelbs Family Office

Elevian

Elevian’s founders discovered circulating blood factors that regulate aging, including GDF11, which broadly stimulate regeneration of brain, heart, pancreas, muscle, and other tissues.  Elevian is developing therapeutics that stimulate regenerative capacity, to treat and prevent age-related disease.

<div>Elevian develops medicines that restore regenerative capacity, with the potential to treat and prevent many age-related diseases. The company researches the tissue and organic regeneration capabilities acquired by older animals after being transfused with the blood of young animals and develops drugs to restore regenerative capacity in humans, with the potential to halt and treat a range of aging-related diseases.</div>

Longevity Tech

Elevian snags $40M for stroke recovery and age-related diseases

<div>
 
 Elevian develops medicines that restore regenerative capacity, with the potential to treat and prevent many age-related diseases. The company researches the tissue and organic regeneration capabilities acquired by older animals after being transfused with the blood of young animals and develops drugs to restore regenerative capacity in humans, with the potential to halt and treat a range of aging-related diseases.
 
 
 
 
 Elevian&rsquo;s programs in the pipeline utilize recombinant growth differentiation factor 11 (rGDF11) and other modulators of the GDF11 pathway. These are targeted at neurologic diseases and strokes, where the focus is to prevent patients from becoming permanently disabled or dying post-stroke. These programs are in preclinical stages as of October 2023.&nbsp;&nbsp;
 
 
 
 
 GDF11 is a circulating blood factor that is claimed to stimulate regeneration broadly and consistently in multiple tissues and organs. rGDF11 is claimed to promote neovascularization (new blood vessel formation), stimulate neurogenesis (new neuron formation), and reduce inflammation. The effects of rGDF11 seem to be independent of the type of injury (clots vs. bleeds). In addition, it is claimed that rGDF11 can promote recovery and regeneration in several preclinical models of aging-related diseases, including cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.
 
 
 
 
 Elevian holds exclusive worldwide rights to a portfolio of patents from Elevian, Harvard, and affiliated research partners. These include the patents for the pharmaceutical composition comprising a GDF11 polypeptide, the use of GDF11 to treat stroke, obesity, type II diabetes, and a number of aging-related diseases, and new compositions to modulate GDF11 activity.
 
 
 
 
 Funds and financials
 
 
 
 
 As of November 2023, the company&rsquo;s latest funding round was in September 2021, where the company raised USD 40 million in Series A funding led by Prime Movers Lab. The funds were intended to be used to submit an investigational new drug application, scale manufacturing, and complete Phase I clinical trials for its lead indication of stroke recovery.
 
 
 
 
 
</div>

Mitrix Bio addresses mitochondrial dysfunction by developing bioreactor-grown mitochondria to be transplanted into the human body to regenerate organs, reverse age-related disease, and support other longevity therapies. Large-scale mitochondrial transfusion could potentially treat Alzheimer's, Parkinson's, AMD, glaucoma, infectious disease, and other age-related diseases, along with children's mitochondrial mutation diseases. The company believes that the same technique can be used in healing and reducing frailty for the aged, speeding healing of wounded soldiers, or combating aging itself. The company is developing technologies and infrastructure targeting to reverse mitochondrial mtDNA degeneration targeting parts of the body that most commonly experience mitochondrial dysfunction. The company has six programs at preclinical stages in its pipeline (as of October 2023). These programs are focused on immunology (infectious diseases), neurology (Alzheimer's/Parkinson’s), ophthalmology (AMD/glaucoma), dermatology (aking aging/wound healing), musculo-skeletal (sarcopenia, frailty), and organs (liver/kidney).

Mitrix Bio

Sierra Sciences engages in research to develop therapeutics targeting aging based on telomeres. These get shorter as people age and lead to various diseases. The company aims to extend the human lifespan and healthspan based on addressing telomere shortening as a solution to address effects of human aging. The company receives royalties from the sale of Product B, a nutraceutical supplement developed in a partnership and distributed through Isagenix. The company develops therapeutics focused on pharmaceuticals to slow and reverse the aging process, nutraceuticals to slow and reverse aging, telomere protection, telomere length measurement, cancer diagnostics, cancer treatments, telomerase gene therapy, immortal pet cloning, and human growth hormones.

Sierra Sciences

Turn.bio is a biotech company developing therapies based on epigenetic reprogramming and reverse cellular aging. The company develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. This is focused on reprogramming the epigenome to restore capabilities that are often lost with age. Its proprietary ERA Platform can reportedly be used to revitalize different cells throughout the body. The company is exploring its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis, and ophthalmology. The platform is claimed to enable control of the time, duration, and dosage of transcription factors to optimize the mRNA cocktail for each indication. This reportedly allows control of reprogramming, moving the epigenome to a more youthful state step-by-step by carefully pulsing the cell with the transcription factors. The company claims to have discovered that the use of quiescent stem cells can significantly help to repair or replace specific types of damaged tissue. In these cases, the company reportedly deploys its Artificial Niche (AN) technology to protect the stem cells. AN technology combines stem-cell biology with biomolecular materials engineering and micro-fabrication technologies to generate novel cell-culture platforms that mimic crucial biochemical or structural aspects of the niche. turn.bio’s novel eTurna Platform can reportedly deliver a variety of cargoes requiring different routes of administration and be fine-tuned and targeted to specific tissue and cells. Funding and financials In July 2022, biotech company VitaDAO made a USD 1,000,000 investment into turn.bio. The investment was intended to fund turn.bio’s preclinical efficacy testing phase for mRNA therapeutics for dermatological and ophthalmological longevity research.

Turn.bio

<div>
 
 AgeX Therapeutics is a biotech company engaged in the development and commercialization of novel therapeutics focused on aging.&nbsp;
 
 
 
 
 The company is building upon the foundation of its proprietary technologies, such as PureStem and induced Tissue Regeneration, to develop medicines targeting aging and related diseases. Through PureStem, the company claims to have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging. iTM is claimed to be the company's longevity platform intending to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.
 
 
 
 
 Its product pipeline includes two cell-based and two iTR-based product candidates in development: AGEX-BAT1 and AGEX-VASC1.
 
 
 AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders, such as type 2 (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy in the discovery stage of development, composed of young regenerative vascular-forming cells.&nbsp;
 
 
 
 
 The company was founded by leading gerontologist, bioentrepreneur, and Ph.D. holder Dr. Michael D. West,&nbsp; a highly-regarded pioneer in cellular aging, stem cell research, telomerase, and cloning.
 
 
 
 
 In August 2023, the company entered a merger agreement with Serina Therapeutics, a privately held, clinical-stage biotech company developing a pipeline of therapies for the treatment of Parkinson&rsquo;s disease and other neurological diseases. Under this, Serina merged with a wholly-owned subsidiary of AgeX therapeutics in an all-stock transaction. The combined company continues under the &ldquo;Serina Therapeutics&rdquo; name and focuses on advancing Serina&rsquo;s pipeline of small-molecule drug candidates targeting central nervous systems indications.
 
 
 
 
 Funding and financials
 
 
 
 
 The company recorded total revenue of USD 34 million in 2022, compared to USD 144 million in 2021 (77% decrease). This is due to absence of grant revenues in 2022, as opposed to 2021, where grant revenue was USD 104 million. Net loss reported for 2022 was USD 10.5 million, compared to the loss of USD 8.7 million recorded in the preceding year.
 
 
 
 
 
</div>

AgeX Therapeutics

<div>
 
 UNITY Biotechnology develops therapeutics targeting age-related diseases, particularly focusing on therapy in ophthalmologic diseases, including diabetic macular edema and age-related neurologic conditions.
 
 
 
 
 Its therapeutics are intended to selectively eliminate or modulate senescent cells to slow down, stop, or even reverse age-related disease and restore aging or damaged tissue to a more functionally healthy state. The approach is expected to remedy diseases of aging, such as retinopathies, neurodegenerative disorders, fibrosis, and cancer.&nbsp;
 
 
 
 
 The company&rsquo;s lead drug candidate, UBX1325, is evaluated for the treatment of age-related diseases of the eye, including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival. It is claimed that UBX1325 demonstrated a statistically significant and clinically meaningful improvement in mean best corrected visual acuity (BCVA) across 48 weeks compared to sham treatment in the Phase II BEHOLD study in patients with DME. A Phase IIb study (ASPIRE) was enrolling patients with DME to evaluate UBX1325 head-to-head against aflibercept.
 
 
 
 
 UNITY Biotechnology was also developing programs targeting the Tie2 signaling pathway for therapeutic benefit. Tie2 pathway activity declines with age and causes the loss of vascular barrier integrity and diseased blood vessel formation in the eye. The Tie2/VEGF bispecific molecule targets two pathways believed to be core to disease progression in DME and AMD. Another program directed at Tie2 activation is in preclinical studies for multiple indications.
 
 
 
 
 The company's neurology programs intend to explore new mechanisms for cognitive benefit, and the company licensed its &alpha;-Klotho program, UBX2089, to Jocasta Neuroscience for development and commercialization in cognitive dysfunction associated with neurological and psychiatric conditions.
 
 
 
 
 
</div>

UNITY Biotechnology

Companies conducting R&D on cell and gene therapies that aim to repair or replace dysfunctional cells to address the root cause of age-related diseases

Companies involved in the development of novel small molecules or chemical drugs that target specific proteins or pathways in the body to treat age-related diseases as well as the identification of existing drugs that can be repurposed for the treatment of such diseases

Platforms and tools that collect and analyze patient data to detect, prevent, and monitor age-related damage

Dietary supplements and wellness products that are developed through scientific approaches to slow down age-related damage

Companies developing therapies for age-related sensory deficiencies such as vision and hearing loss

Companies in the neurotechnology sector that develop tools such as neuroimaging and neurostimulation devices; pharmaceutical drugs and therapies aimed at treating age-related neurological conditions

Diagnostic tests and services focused on assessing the health of an individual's gut microbiome and their metabolic processes to identify internal age-related issues

Platforms and tools that provide personalized remedies for general well-being and to mitigate the risk of age-related diseases

Genomics is used for diagnostics and to offer tailored treatment for age-related diseases

Offers digital platforms and devices that allow individuals to measure, track, and potentially modify the physiological changes associated with aging

AL/ML is used in drug discovery and development as well as diagnostic tools to support longevity-related treatments

Elevian

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless